Cumulative cardiotoxic effect of bleomycin in experiment
Keywordsbleomycin, cardiotoxic effect, cancer patients
The aim of the study was to evaluate the cumulative toxic effect of bleomycin under experimental conditions
Material and Methods. The study was conducted in the Research Institute of Transport Medicine during 2016-2021. The experimental model of the cardiotoxic effect of the bleomycin was performed using the medication "Bleocin" manufactured by Nippon Kayaku Co., Ltd. (Japan). According to the task, the study was performed on 10 mature rats of both sexes of the Wistar line with a body weight of 237 ± 20 g.
Rats were housed in standard vivarium conditions of Odessa National Medical University. Animals were divided into 2 groups: experimental group (n = 5) and control (n = 5). Bleomycin animals of the experimental group were obtained intraperitoneally at a dose of 0.5 IU / kg on 1st and 8th days. Withdrawal of animals from the experiment was performed on the 5th, 14th and 28th day of the experiment, followed by morphological and morphometric examination.
The material after weighing and morphometry was fixed with a neutral 10% formalin solution and poured into paraffin. Histological sections were stained with hematoxylin-eosin, MSB, Van Gizon. Performed light microscopy.
After two weeks there was a decrease in myocardial weight by 7-10% from baseline, there were pronounced dystrophic changes in the myocardium. Repeated administration of bleomycin has a cumulative cardiotoxic effect leading to irreversible changes in the myocardium and endothelial dysfunction clinically manifested by heart attack, vascular pathology at significant cumulative doses of bleomycin. Morphofunctional changes of the right ventricle are prominent and considered to be pathognomic for bleomycin toxicity.
Conclusions: 1. Bleomycin has a cumulative toxic effect on the myocardium of mammals
2. The severity of the cardiotoxic effect of bleomycin is proportional to the tissue concentration of the drug, which is proportional to the duration of exposure
Akazawa H. [Cardiotoxicity of Cancer Chemotherapy - Mechanisms and Therapeutic Approach]. Gan To Kagaku Ryoho. 2017 Dec;44(13):2058-2063. Japanese. PMID: 29361617.
Nakauchi K, Ido S, Sumikawa S, Kawazoe H, Hasebe S, Asai H, Takeuchi K, Matsuo M, Yakushijin Y. [Assessment of Chemotherapy-Induced Adverse Events Using a Sharing System of Patient-Reported Information via a Touch Panel]. Gan To Kagaku Ryoho. 2020 May;47(5):801-806. Japanese. PMID: 32408323.
Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009 Jun 16;53(24):2231-47. doi: 10.1016/j.jacc.2009.02.050. PMID: 19520246.
Lenneman CG, Sawyer DB. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment. Circ Res. 2016 Mar 18;118(6):1008-20. doi: 10.1161/CIRCRESAHA.115.303633. PMID: 26987914.
López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D, Cardinale D, Canales Albendea M, Feliu Batlle J, Rodríguez Rodríguez I, Rodríguez Fraga O, Albaladejo A, Mediavilla G, González-Juanatey JR, Martínez Monzonis A, Gómez Prieto P, González-Costello J, Serrano Antolín JM, Cadenas Chamorro R, López Fernández T. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020 May 7;41(18):1720-1729. doi: 10.1093/eurheartj/ehaa006. PMID: 32016393.
Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016 Jul;66(4):309-25. doi: 10.3322/caac.21341. Epub 2016 Feb 26. PMID: 26919165.
Henry's Clinical Diagnosis and Management by Laboratory Methods by Richard A. McPherson, Matthew R. Pincus NY., Elsevier; 24th edition 2021 1618 p.
Zaporozhyan VM, Aryaev ML Bioethics and biosafety. K.: Zdorov'ya, 2013. -456 p.
Khalafyan AA Statistica 6. Mathematical statistics with elements of the theory of probability. / A. A. Khalafyan M., Binom, - 2011 – 326 p.
How to Cite
Copyright (c) 2021 A. Gozhenko, O. Bestanchuk, O. Kaschenko, T. Narbutova
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 189
Number of citations: 0